BIO-key International Stock to Be Suspended on Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Should l Buy BKYI?
BIO-key International announced that it has received written notification from The Nasdaq Stock Market LLC that the trading of its common stock will be suspended on Nasdaq effective with the markets' close today, May 12. BIO-key has received approval from OTC Markets Group for its common stock to be quoted on the OTC Market under the same symbol commencing May 13. "Through shareholder support and our concerted efforts to regain compliance with Nasdaq's continued listing standards via a reverse split, we have restored our share price to a level well in excess of Nasdaq's $1 minimum closing bid price requirement. Unfortunately, due to the timing of the reverse split, we were unable to maintain this share price level for the previous 10 trading days and our listing currently has been suspended," said Michael DePasquale, chairman and CEO. "We are undertaking corrective measures to regain compliance, including retaining expert listing consultants to assist us in this process. With their guidance, we are taking steps that we believe provide us the best opportunity to have trading resume on Nasdaq expeditiously".
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BKYI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BKYI
About BKYI
BIO-key International, Inc. is a provider of workforce and customer identity and access management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication. The Company’s IAM platform enables secure work-from-anywhere for enterprise, education, and government customers using secure multi-factor authentication (MFA). Its products include PortalGuard and PortalGuard Identity-as-a-Service (IDaaS) enterprise IAM, WEB-key biometric civil and large-scale ID infrastructure, MobileAuth mobile phone authentication application for iOS and Android, and quality accessory fingerprint scanner and FIDO-compliant hardware to provide complete solution for identity-innovating customers. Its PortalGuard is a cloud-based identity platform that allows its customers to integrate with any cloud or on-premise SaaS application, service or cloud host, as well as Windows device authentication through a single IAM platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BIO-key Q1 Earnings Report Analysis
- Earnings Performance: BIO-key reported a Q1 GAAP EPS of -$0.15 with revenues of $2.15 million, reflecting a 34% year-over-year increase, yet it missed expectations by $0.05 million, indicating challenges in revenue growth.
- Future Outlook: The company anticipates a 65% revenue increase in Q2 2025 to approximately $2.8 million compared to $1.7 million in Q2 2025, showcasing confidence in future growth while needing to overcome current financial pressures.
- Profitability Expectations: BIO-key expects to achieve profitability in H1 2026 with projected revenues of $5 million, a significant turnaround from a net loss of $1.9 million in H1 2025, indicating efforts to improve financial health.
- Cash Position: The cash position for H1 2026 is expected to remain in line with the current status, and despite challenges, the company maintains an optimistic outlook for revenue growth and improved bottom line for the full year 2026.
See More
BIO-key International Reports 34% Revenue Growth in Q1 2026
- Significant Revenue Growth: BIO-key International reported a 34% increase in Q1 2026 revenues to $2.1 million, driven by new customer acquisitions and expanded deployments, laying a solid foundation for future market expansion.
- Strong Gross Margin: The company maintained a gross margin of 82% in Q1 2026, consistent with 2025, highlighting the advantages of high-margin license fee revenue and sales of fully reserved inventory, which bolster profitability.
- Improved Net Loss: Although the net loss for Q1 2026 was $165,036, an improvement from $736,545 in Q1 2025, ongoing privacy and regulatory challenges in the U.S. market could impact future financial performance.
- Optimistic Market Outlook: BIO-key's partnership with DLT Solutions provides a streamlined procurement path for public sector customers, which is expected to enhance market penetration in defense and financial services, strengthening its long-term growth potential.
See More
BIO-key International Q1 2026 Earnings Call Insights
- Significant Revenue Growth: BIO-key International reported a 34% year-over-year revenue increase in Q1 2026, reaching $2.1 million compared to $1.6 million in Q1 2025, indicating strong performance from new customer acquisitions and long-term deployments in defense and financial services.
- Hardware Revenue Doubling: The company's hardware revenue surged over 100% to approximately $531,000, reflecting a significant increase in hardware demand as larger licensing opportunities close, thereby enhancing profit margins.
- NASDAQ Return Plan: The company is actively pursuing its NASDAQ appeal process, with a hearing scheduled for June 16, and management expresses optimism about returning to NASDAQ trading by summer, which could boost investor confidence and market recognition.
- Positive Future Outlook: Management anticipates profitability and positive cash flow in Q2, emphasizing that as revenue scales up, profits will significantly increase, indicating the company's growth potential and competitive positioning in the market.
See More
BIO-key International Receives Nasdaq Notice for Filing Delay
- Nasdaq Notice: BIO-key International received a notice from Nasdaq for failing to comply with listing requirements due to a delay in filing its fiscal 2025 annual report, which pertains to Listing Rule 5250(c)(1) requiring timely submission of financial reports to the SEC.
- Impact Assessment: Despite the notice, BIO-key stated that it has no immediate impact on the listing or trading of its shares, indicating the company's stability in compliance matters.
- Audit Progress: The company is working with auditors and expects to submit the Form 10-K next week, demonstrating its proactive approach and plans to resolve compliance issues.
- Future Outlook: BIO-key anticipates approximately $2.2 million in revenue for Q1 2026, targeting breakeven and profitability in 2026, reflecting the company's confidence in its future financial health.
See More
BIO-key International Inc Reports Mixed 2025 Financial Results
- Revenue Growth Expectations: BIO-key International Inc anticipates Q1 2026 revenue of approximately $2.2 million, reflecting a 37% increase over Q1 2025, indicating potential recovery in the market despite a 12% decline in total revenue to $6.1 million in 2025.
- Hardware and Service Revenue Increase: In 2025, hardware revenue surged over 100% to $1.3 million, while service revenue rose 6% to $1.2 million, demonstrating ongoing growth in product sales and services, even as overall gross margin decreased to 77.5%.
- Improved Cash Flow and Asset Position: By the end of 2025, the company reported cash reserves of $2.7 million, up more than $2 million from 2024, enhancing financial stability, while book value increased from $3.8 million to $7.6 million, reflecting healthy asset growth.
- Increased Net Loss: The net loss for 2025 rose to $4.6 million, or $0.69 per share, compared to $4.3 million and $2.09 per share in 2024, highlighting challenges faced during the transition, particularly in the slower-than-expected brand shift in the EMEA region.
See More
BIO-key International Q4 2025 Earnings Call Insights
- Revenue Expectations Rise: BIO-key anticipates Q1 2026 revenue of approximately $2.2 million, representing a 37% increase over Q1 2025, indicating significant progress in revenue recovery that is expected to enhance overall financial performance.
- Strategic Transition Completed: The company completed its strategic shift to selling only BIO-key branded solutions in 2025, which is expected to improve gross margins and enhance growth prospects, particularly in the competitive EMEA market.
- Cost Control Effectiveness: In 2025, BIO-key successfully reduced SG&A expenses by nearly $800,000, an 11% decrease, while cash reserves reached $2.7 million, demonstrating ongoing improvements in operational efficiency.
- Product Release Progress: BIO-key formally introduced the FBI FAP 20 certified EcoID III fingerprint scanner and expects PortalGuard 7.0 to be released in Q2 2026, which will further strengthen its market position in regulated industries.
See More
BIO-key Q1 Earnings Report Analysis
- Earnings Performance: BIO-key reported a Q1 GAAP EPS of -$0.15 with revenues of $2.15 million, reflecting a 34% year-over-year increase, yet it missed expectations by $0.05 million, indicating challenges in revenue growth.
- Future Outlook: The company anticipates a 65% revenue increase in Q2 2025 to approximately $2.8 million compared to $1.7 million in Q2 2025, showcasing confidence in future growth while needing to overcome current financial pressures.
- Profitability Expectations: BIO-key expects to achieve profitability in H1 2026 with projected revenues of $5 million, a significant turnaround from a net loss of $1.9 million in H1 2025, indicating efforts to improve financial health.
- Cash Position: The cash position for H1 2026 is expected to remain in line with the current status, and despite challenges, the company maintains an optimistic outlook for revenue growth and improved bottom line for the full year 2026.
See More
BIO-key International Reports 34% Revenue Growth in Q1 2026
- Significant Revenue Growth: BIO-key International reported a 34% increase in Q1 2026 revenues to $2.1 million, driven by new customer acquisitions and expanded deployments, laying a solid foundation for future market expansion.
- Strong Gross Margin: The company maintained a gross margin of 82% in Q1 2026, consistent with 2025, highlighting the advantages of high-margin license fee revenue and sales of fully reserved inventory, which bolster profitability.
- Improved Net Loss: Although the net loss for Q1 2026 was $165,036, an improvement from $736,545 in Q1 2025, ongoing privacy and regulatory challenges in the U.S. market could impact future financial performance.
- Optimistic Market Outlook: BIO-key's partnership with DLT Solutions provides a streamlined procurement path for public sector customers, which is expected to enhance market penetration in defense and financial services, strengthening its long-term growth potential.
See More
BIO-key International Q1 2026 Earnings Call Insights
- Significant Revenue Growth: BIO-key International reported a 34% year-over-year revenue increase in Q1 2026, reaching $2.1 million compared to $1.6 million in Q1 2025, indicating strong performance from new customer acquisitions and long-term deployments in defense and financial services.
- Hardware Revenue Doubling: The company's hardware revenue surged over 100% to approximately $531,000, reflecting a significant increase in hardware demand as larger licensing opportunities close, thereby enhancing profit margins.
- NASDAQ Return Plan: The company is actively pursuing its NASDAQ appeal process, with a hearing scheduled for June 16, and management expresses optimism about returning to NASDAQ trading by summer, which could boost investor confidence and market recognition.
- Positive Future Outlook: Management anticipates profitability and positive cash flow in Q2, emphasizing that as revenue scales up, profits will significantly increase, indicating the company's growth potential and competitive positioning in the market.
See More
BIO-key International Receives Nasdaq Notice for Filing Delay
- Nasdaq Notice: BIO-key International received a notice from Nasdaq for failing to comply with listing requirements due to a delay in filing its fiscal 2025 annual report, which pertains to Listing Rule 5250(c)(1) requiring timely submission of financial reports to the SEC.
- Impact Assessment: Despite the notice, BIO-key stated that it has no immediate impact on the listing or trading of its shares, indicating the company's stability in compliance matters.
- Audit Progress: The company is working with auditors and expects to submit the Form 10-K next week, demonstrating its proactive approach and plans to resolve compliance issues.
- Future Outlook: BIO-key anticipates approximately $2.2 million in revenue for Q1 2026, targeting breakeven and profitability in 2026, reflecting the company's confidence in its future financial health.
See More
BIO-key International Inc Reports Mixed 2025 Financial Results
- Revenue Growth Expectations: BIO-key International Inc anticipates Q1 2026 revenue of approximately $2.2 million, reflecting a 37% increase over Q1 2025, indicating potential recovery in the market despite a 12% decline in total revenue to $6.1 million in 2025.
- Hardware and Service Revenue Increase: In 2025, hardware revenue surged over 100% to $1.3 million, while service revenue rose 6% to $1.2 million, demonstrating ongoing growth in product sales and services, even as overall gross margin decreased to 77.5%.
- Improved Cash Flow and Asset Position: By the end of 2025, the company reported cash reserves of $2.7 million, up more than $2 million from 2024, enhancing financial stability, while book value increased from $3.8 million to $7.6 million, reflecting healthy asset growth.
- Increased Net Loss: The net loss for 2025 rose to $4.6 million, or $0.69 per share, compared to $4.3 million and $2.09 per share in 2024, highlighting challenges faced during the transition, particularly in the slower-than-expected brand shift in the EMEA region.
See More
BIO-key International Q4 2025 Earnings Call Insights
- Revenue Expectations Rise: BIO-key anticipates Q1 2026 revenue of approximately $2.2 million, representing a 37% increase over Q1 2025, indicating significant progress in revenue recovery that is expected to enhance overall financial performance.
- Strategic Transition Completed: The company completed its strategic shift to selling only BIO-key branded solutions in 2025, which is expected to improve gross margins and enhance growth prospects, particularly in the competitive EMEA market.
- Cost Control Effectiveness: In 2025, BIO-key successfully reduced SG&A expenses by nearly $800,000, an 11% decrease, while cash reserves reached $2.7 million, demonstrating ongoing improvements in operational efficiency.
- Product Release Progress: BIO-key formally introduced the FBI FAP 20 certified EcoID III fingerprint scanner and expects PortalGuard 7.0 to be released in Q2 2026, which will further strengthen its market position in regulated industries.
See More
